

# It is illegal to post this copyrighted PDF on any website. Spontaneous Ejaculation Associated With Atomoxetine

Abid Rizvi, MDa,\*; Sushma Srinivas, MDb; and Shailesh Jain, MDa

A tomoxetine is US Food and Drug Administration approved to treat attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults. It acts through selective norepinephrine reuptake inhibition.<sup>1</sup>

Sexual side effects with atomoxetine reported in adults include erectile dysfunction, dysmenorrhea, ejaculation delayed/ejaculation disorder, and decreased libido.<sup>2</sup> In addition, spontaneous ejaculation with or without sexual arousal is associated with many psychotropics, including venlafaxine, methylphenidate, and amphetamine.<sup>3</sup> We share our unique experience with a case of spontaneous ejaculation related to atomoxetine, its presentation, and its clinical course, which we think will be helpful for many clinicians.

## **Case Report**

The patient was a 39-year-old medically healthy White man who met DSM-5 criteria for adult ADHD. He had no other psychiatric or medical diagnosis. The only psychotropic he had ever taken was methylphenidate for ADHD, which was started at age 10 years. He denied any adverse effects from methylphenidate, but stopped taking it at age 24, as he thought he had grown out of ADHD. The patient was a social drinker with 1 to 2 beers on the weekend and denied having used any other drugs. He lived with his wife and 2 kids, was sexually active, and experienced no sexual problems at baseline. He was employed with a large company. Physical and mental status examinations were unremarkable. His body mass index was 35 kg/m<sup>2</sup>, blood pressure was 125/78 mm Hg, and baseline laboratory results, including complete blood count, liver function, kidney function test, and thyroid-stimulating hormone, were within the normal range. His urine drug screen was negative. The patient wanted to try a nonstimulant. So, he was started on atomoxetine 40 mg, which was increased to 80 mg in 1 week.

At 1-month follow-up, the patient reported that after 2 days of starting atomoxetine, he started ejaculating without erection once a day when he was awake. The patient

<sup>a</sup>Department of Psychiatry, Texas Tech University Health Science Center at Permian Basin, Odessa, Texas

Prim Care Companion CNS Disord 2022;24(3):21cr03136

**To cite:** Rizvi A, Srinivas S, Jain S. Spontaneous ejaculation associated with atomoxetine. *Prim Care Companion CNS Disord*. 2022;24(3):21cr03136.

**To share:** https://doi.org/10.4088/PCC.21cr03136

© Copyright 2022 Physicians Postgraduate Press, Inc.

stated that masturbation, porn viewing, sensual/erotic thoughts in his mind, or sexual activity did not precede these ejaculations. Instead, the patient experienced these ejaculations as involuntary and with no orgasmic sensations. These spontaneous ejaculations increased in frequency with an increase in the atomoxetine dose to 80 mg/d. Eventually, he experienced such ejaculations 2 to 3 times a day. The patient felt embarrassed because these ejaculations often happened suddenly in social situations. Nevertheless, the patient remained sexually active with his wife and denied any sexual dysfunction. Urogenital consultation revealed no abnormality.

We recommended stopping the atomoxetine with follow-up in 1 week. The spontaneous ejaculation stopped after 5 days of discontinuing atomoxetine. We started the patient on methylphenidate extended release 18 mg. At 1-month follow-up, he reported that he had not experienced spontaneous ejaculation with methylphenidate.

# Discussion

The sympatric system regulates ejaculation latency time. Ejaculation has an emission and expulsion phase and is controlled by the autonomic nervous system. <sup>4</sup> Atomoxetine induces adrenergic activity by inhibiting the reuptake of norepinephrine, leading to decreased ejaculatory latency and inducing spontaneous ejaculation. <sup>5</sup>

There are similar cases in the literature (Table 1).<sup>6-9</sup> Spontaneous ejaculation started shortly after starting atomoxetine, and there was complete resolution after its discontinuation. Our case is unique because the patient had no comorbid medical or psychiatric diagnosis and was not on any other medication, and the frequency of spontaneous ejaculation increased with the increase in dose of atomoxetine, making the relationship between the drug and adverse effect more likely. We used the Naranjo Adverse Drug Reaction Probability Scale,<sup>10</sup> which had a score of 7 interpreted as "probable."

In 3 of 4 cases reported in the literature, the patients had no orgasm associated with ejaculation, while one had an orgasm. <sup>6-9</sup> Orgasm with ejaculation requires activation of different neuronal circuits. This case shows that ejaculation can occur with no orgasm. However, we are at a loss to explain why the patient did not have spontaneous ejaculation with amphetamine and methylphenidate despite affecting similar neurochemicals.

Published online: May 24, 2022.
Relevant financial relationships: None.
Funding/support: None.

<sup>&</sup>lt;sup>b</sup>AJ Institute of Medical Sciences and Research Center Mangalore, Karnataka, India

<sup>\*</sup>Corresponding author: Abid Rizvi, MD, Texas Tech University Health Science Center, 2301 W Michigan Ave, Midland, TX 79701 (abidrizvi021@gmail.com).

# Table 1. Cases of Atomoxetine-Associated Spontaneous Ejaculation in the Literature

#### Comorbid Diagnosis / Age/Sex Author/Year Start of Symptom Other Associated Features Other Medication Outcome Yaylacı et al, 20206 16 y/male 3 days after start of No arousal or erection Not specified in case report Complete atomoxetine 40 mg resolution after stopping McGrane and 42 y/male 2 days after start of Urinary hesitancy with milky, white-colored Mood disorder, alcohol use Campbell, 2021<sup>7</sup> atomoxetine 40 mg discharge; urinary frequency causing him to disorder Seroquel 50 mg/d and urinate 2 times/hour; pain at the tip of his penis; urinalysis was normal hydroxyzine 25 mg/3 times/d MacDonald et al, 24 y/male After start of Spontaneous ejaculation with orgasmic Not specified in case report atomoxetine 80 mg (days 2019<sup>8</sup> activity 2 to 3 times/d not specified in study) Oosterhuis et al, 40 y/male 3 weeks after start of Ejaculation after micturition urgency Not specified in case report $2012^{3}$ atomoxetine (dose not 8 times/d without arousal specified in study)

**Patient consent:** Informed consent was received from the patient to publish the case report, and information has been de-identified to protect anonymity.

### REFERENCES

- 1. Strattera (atomoxetine) [package insert]. Lilly LLC; 2020.
- 2. Clemow DB, Bushe C, Mancini M, et al. A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities. Neuropsychiatr Dis Treat. 2017:13:357-371.
- 3. Oosterhuis I, Heijting L, Van Puijenbroek EP. Spontaneous ejaculation with the use of ADHD drugs. Drug Saf. 2009;32(10):409.
- Clement P, Giuliano F. Physiology and pharmacology of ejaculation. Basic Clin Pharmacol Toxicol. 2016;119(suppl 3):18-25.
- Sivrioglu EY, Topaloglu VC, Sarandol A, et al. Reboxetine induced erectile dysfunction and spontaneous ejaculation during defecation and

- micturition. Prog Neuropsychopharmacol Biol Psychiatry. 2007:31(2):548-550.
- 6. Yaylacı F, Şahbudak B, Küçük Ö. Spontaneous ejaculation induced with atomoxetine. Psychopharmacol Bull. 2020;50(1):40-43.
- 7. McGrane IR, Campbell TJ. Probable genitourinary adverse events associated with atomoxetine in an adult male: a case report. J Pharm Pract. 2021;34(6):962-965.
- 8. MacDonald T, Wimalaguna PS, Akosile W. Case report: severe and treatment-resistant spontaneous ejaculation secondary to atomoxetine. Australas Psychiatry. 2019;27(2):198-199.
- Oosterhuis I, Heijting L, van Puijenbroek E. Spontaneous ejaculation with the use of noradrenergic reuptake inhibitors. Eur J Clin Pharmacol. 2012;68(10):1461-1462.
- 10. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. . 1981;30(2):239–245.